Disease relevance of Coretal

• Variations in mean plasma levels and beta-adrenoceptor blockade (measured by inhibition of exercise tachycardia) were considerably reduced on the 10/170 Oros once-daily compared with the Trasicor 80 mg twice-daily regimen [1].
• RESULTS: According to the effects on the mucosal epithelium of the slugs the following rank order of increasing toxicity was established: PBS, HP-beta-CD (5%), beta-CD (1.8%) and oxprenolol hydrochloride (1%) < DDPC (1%) < STDHF (1%) < BAC (1%), SDC (1%) and propranolol hydrochloride (1%) [2].
• In a randomized double-blind study of 175 patients with mild-to-moderate hypertension, oxprenolol hydrochloride (160-480 mg) given once daily was compared with the same drug given twice daily for efficacy, safety, and tolerability [3].
• The use of Trasicor and hypothiazide in the treatment of hypertension and hypertensive angina pectoris [4].

High impact information on Coretal

• With Slow Trasicor heart rate responses had returned to baseline values by this time [5].
• We have therefore studied the effect on blood pressure, heart rate and plasma renin activity of the beta blocking drug oxprenolol (Trasicor) which has considerable intrinsic sympathomimetic activity, both alone and in combination with the benzothiadiazine cyclopenthiazide [6].
• Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy [7].
• 2. Megaloporous tablets showed bioequivalence with the reference sustained release product Slow-Trasicor [8].
• The efficacy of oxprenolol (Trasicor) and propranolol in controlling anxiety was compared in a double-blind study of patients with anxiety and tension [9].

Chemical compound and disease context of Coretal

• Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice [10].

Biological context of Coretal

• In a sutdy of oxprenolol (Trasicor) in the treatment of angina in general practice, a simple non-comparative assessment of efficacy indicated complete or substantial relief of symptoms in nearly 80 percent of patients [11].

Analytical, diagnostic and therapeutic context of Coretal

• The assay was applied to the content uniformity test of three oxprenolol hydrochloride tablet formulations of different strengths and the contents of a 2-mg dry ampule for intravenous/intramuscular injection [12].

References